ISPOR 2024 Home
Toggle navigation
About
News Center
Award Winners
Program
Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Exhibitor Directory
Media Partners
Photo Gallery
ISPOR
2024
May 5-8, 2024
Home
Events
Past Conferences
ISPOR 2024
Program
Plenary Sessions
Session
Economic Evaluation and Budget Impact of Brigatinib Versus Other ALK-Inhibitors for First-Line ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Treatment in the Brazilian Private Healthcare System
May 7, 2024, 16:30 PM
«
561
562
(current)
563
564
565
566
567
568
569
570
»